Circulating syndecan-1 is reduced in pregnancies with poor fetal growth and its secretion regulated by matrix metalloproteinases and the mitochondria.
Adult
Area Under Curve
Birth Weight
Cell Hypoxia
Delivery, Obstetric
Diabetes, Gestational
/ blood
Electron Transport
/ drug effects
Female
Fetal Growth Retardation
/ blood
Gestational Age
Humans
Hypertension
/ blood
Infant, Newborn
Infant, Small for Gestational Age
Matrix Metalloproteinases
/ physiology
Metformin
/ pharmacology
Mitochondria
/ drug effects
Organ Size
Overweight
/ blood
Placenta
/ metabolism
Pre-Eclampsia
/ blood
Pregnancy
Pregnancy Complications
/ blood
ROC Curve
Smoking
/ blood
Syndecan-1
/ blood
Trophoblasts
/ enzymology
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
16 08 2021
16 08 2021
Historique:
received:
07
06
2021
accepted:
30
07
2021
entrez:
17
8
2021
pubmed:
18
8
2021
medline:
16
11
2021
Statut:
epublish
Résumé
Fetal growth restriction is a leading cause of stillbirth that often remains undetected during pregnancy. Identifying novel biomarkers may improve detection of pregnancies at risk. This study aimed to assess syndecan-1 as a biomarker for small for gestational age (SGA) or fetal growth restricted (FGR) pregnancies and determine its molecular regulation. Circulating maternal syndecan-1 was measured in several cohorts; a large prospective cohort collected around 36 weeks' gestation (n = 1206), a case control study from the Manchester Antenatal Vascular service (285 women sampled at 24-34 weeks' gestation); two prospective cohorts collected on the day of delivery (36 + 3-41 + 3 weeks' gestation, n = 562 and n = 405 respectively) and a cohort who delivered for preterm FGR (< 34 weeks). Circulating syndecan-1 was consistently reduced in women destined to deliver growth restricted infants and those delivering for preterm disease. Syndecan-1 secretion was reduced by hypoxia, and its loss impaired proliferation. Matrix metalloproteinases and mitochondrial electron transport chain inhibitors significantly reduced syndecan-1 secretion, an effect that was rescued by coadministration of succinate, a mitochondrial electron transport chain activator. In conclusion, circulating syndecan-1 is reduced among cases of term and preterm growth restriction and has potential for inclusion in multi-marker algorithms to improve detection of poorly grown fetuses.
Identifiants
pubmed: 34400721
doi: 10.1038/s41598-021-96077-1
pii: 10.1038/s41598-021-96077-1
pmc: PMC8367987
doi:
Substances chimiques
SDC1 protein, human
0
Syndecan-1
0
Metformin
9100L32L2N
Matrix Metalloproteinases
EC 3.4.24.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
16595Informations de copyright
© 2021. The Author(s).
Références
J Matern Fetal Neonatal Med. 2018 Aug;31(15):1976-1982
pubmed: 28574293
Lancet. 2015 Nov 21;386(10008):2089-2097
pubmed: 26360240
J Pathol. 1999 Dec;189(4):600-8
pubmed: 10629564
Am J Obstet Gynecol. 2020 Oct;223(4):B2-B17
pubmed: 32407785
Clin Obstet Gynecol. 2006 Jun;49(2):236-56
pubmed: 16721104
Mol Cells. 2007 Oct 31;24(2):153-66
pubmed: 17978567
Obstet Gynecol. 2003 Jul;102(1):181-92
pubmed: 12850627
Semin Fetal Neonatal Med. 2004 Oct;9(5):395-401
pubmed: 15691775
Sci Rep. 2019 Jan 18;9(1):235
pubmed: 30659233
Pregnancy Hypertens. 2014 Oct;4(4):287-95
pubmed: 26104818
J Biol Chem. 2003 Dec 19;278(51):51340-6
pubmed: 14534304
Oncol Rep. 2010 Apr;23(4):917-25
pubmed: 20204274
Reprod Biol Endocrinol. 2019 Mar 2;17(1):28
pubmed: 30825879
Cell Stem Cell. 2018 Jan 4;22(1):50-63.e6
pubmed: 29249463
J Perinat Med. 2014 May;42(3):329-38
pubmed: 24222257
Placenta. 2011 Sep;32(9):665-670
pubmed: 21764444
Nat Med. 2020 Mar;26(3):348-353
pubmed: 32161413
Am J Obstet Gynecol. 2016 Mar;214(3):356.e1-356.e15
pubmed: 26721779
FEBS J. 2013 May;280(10):2320-31
pubmed: 23384311
J Matern Fetal Neonatal Med. 2011 May;24(5):708-12
pubmed: 20849205
Clin Chem Lab Med. 2019 Dec 18;58(1):50-58
pubmed: 31622242
Expert Rev Mol Med. 2010 Feb 01;12:e5
pubmed: 20113533
J Histochem Cytochem. 2011 Jun;59(6):615-29
pubmed: 21430259
Placenta. 2019 Dec;88:1-7
pubmed: 31563554
PLoS One. 2016 Jun 14;11(6):e0157608
pubmed: 27299886
BMJ. 2013 Jan 24;346:f108
pubmed: 23349424
Am J Obstet Gynecol. 2000 Dec;183(6):1495-8
pubmed: 11120517
APMIS. 2004 Feb;112(2):89-97
pubmed: 15056224
Virchows Arch. 2013 Sep;463(3):445-58
pubmed: 23807541
Obstet Gynecol. 2014 Aug;124(2 Pt 1):274-283
pubmed: 25004344
Lancet Child Adolesc Health. 2018 Aug;2(8):569-581
pubmed: 30119716
N Engl J Med. 2016 Jan 7;374(1):13-22
pubmed: 26735990
J Physiol. 2016 Mar 1;594(5):1341-56
pubmed: 26377136
Placenta. 1997 Nov;18(8):613-21; discussion 623-6
pubmed: 9364596
J Biol Chem. 2003 Oct 17;278(42):40764-70
pubmed: 12904296
Am J Physiol Endocrinol Metab. 2014 Feb 15;306(4):E404-13
pubmed: 24347055
Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1621-1626
pubmed: 30655345
BMC Cancer. 2008 Jun 30;8:185
pubmed: 18590537
Ultrasound Obstet Gynecol. 2015 Aug;46(2):182-90
pubmed: 25826778
Aust N Z J Obstet Gynaecol. 2007 Aug;47(4):302-6
pubmed: 17627685
Eur J Obstet Gynecol Reprod Biol. 2018 Jun;225:26-34
pubmed: 29631209
Am J Obstet Gynecol. 2018 Feb;218(2S):S725-S737
pubmed: 29275822
Placenta. 2016 Jun;42:1-8
pubmed: 27238707
Placenta. 2007 Jul;28(7):714-23
pubmed: 16962658
Nat Commun. 2020 May 15;11(1):2411
pubmed: 32415092
J Clin Endocrinol Metab. 2015 Jul;100(7):E936-45
pubmed: 25946029
Eur J Cancer. 2004 Jun;40(9):1373-82
pubmed: 15177497